bpc-157 fda compounding category Peptide Review 2026: What This Big Shift Means HIMS jumps more than 7%

HIMS jumps more than 7% after an FDA panel recommends adding BPC 157 to the 503A compounding list potentially opening a new peptide category. The opportunity fits Hims existing telehealth, compounding and customer New FDA peptide advisers could benefit from their own rulings STAT A step towards expanded patient access. This will allow patients to have conversations about these compounds in the clinical setting instead of resorting to a gray market without practitioner oversight or monitoring! 83% of peptide aware Americans want the FDA to make peptides more accessible AOL

SKU: 9948999733 · From clintoncounty708.com